The default privileges for the running service Normand Viewer Service in Beckman Coulter Remisol Advance v2.0.12.1 and prior allows non-privileged users to overwrite and manipulate executables and libraries. This allows attackers to access sensitive data.
Conclusion & alert: CVE-2022-26237 is rated Low Risk (25.3/100): CVSS Medium severity, with low exploitation likelihood (EPSS 0.19%). Mandatory action: Monitor for updates and reassess as exploit intelligence or EPSS changes.
Risk is dynamic; we continuously reassess and refresh what is shown on this page as upstream context changes.
EPSS lead: Daily EPSS estimates relative likelihood of exploitation; percentile ranks this CVE among scored vulnerabilities (higher = more severe relative rank).
| # | Date | Old EPSS score | New EPSS score | Delta (New - Old) |
|---|---|---|---|---|
| 1 | 2026-06-15 | 0.04% | 0.19% | +0.15% |
| 2 | 2025-11-23 | 0.06% | 0.04% | -0.02% |
| 3 | 2025-07-16 | — | 0.06% | — |
Full EPSS history (7 records total)
CVSS metrics for this CVE.
| Base score | Version | Severity | Vector | Exploitability | Impact | Score source |
|---|---|---|---|---|---|---|
| 5.5 | 3.1 | MEDIUM |
|
1.8 | 3.6 | [email protected] |
| Vendor | Product | Version | Raw CPE |
|---|---|---|---|
| beckmancoulter | remisol_advance | <= 2.0.12.1 | cpe:2.3:a:beckmancoulter:remisol_advance:*:*:*:*:*:*:*:* |
| URL | Tags |
|---|---|
| https://pastebin.com/DREqM7AT | Third Party Advisory |
| https://www.beckmancoulter.com/products/clinical-information-management-tools/remisol-advance | Product |